INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Maxim Group from $22.00 to $30.00. They now have a "buy" rating on the stock.
INmune Bio price target raised to $23 from $22 at Scotiabank [Yahoo! Finance]
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
INmune Bio, Inc. (NASDAQ: INMB) had its price target raised by analysts at Scotiabank from $22.00 to $23.00. They now have a "sector outperform" rating on the stock.
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) [Yahoo! Finance]